Salud financiera de hoja de balance de Akero Therapeutics

Salud financiera controles de criterios 5/6

Akero Therapeutics has a total shareholder equity of $846.3M and total debt of $35.7M, which brings its debt-to-equity ratio to 4.2%. Its total assets and total liabilities are $912.2M and $66.0M respectively.

Información clave

4.2%

Ratio deuda-patrimonio

US$35.73m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$903.67m
Patrimonio	US$846.25m
Total pasivo	US$65.99m
Activos totales	US$912.24m

Actualizaciones recientes sobre salud financiera

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

May 04

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

Jan 15

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10

Recent updates

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Oct 01

Akero: Ticking All The Right Boxes In NASH

Sep 23

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Jun 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($560.0M) de AKRO superan a sus pasivos a corto plazo ($19.1M).

Pasivo a largo plazo: Los activos a corto plazo de AKRO ($560.0M) superan a sus pasivos a largo plazo ($25.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: AKRO tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de AKRO ha crecido de 0% a 4.7% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: AKRO tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: AKRO dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 33.2% cada año

Salud financiera de hoja de balance de Akero Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Akero Therapeutics (NASDAQ:AKRO) Is In A Good Position To Deliver On Growth Plans

Recent updates

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis

Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc.

High number of new directors

We're Not Very Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Rate

High number of new directors

President exercised options and sold US$170k worth of stock

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients

President exercised options and sold US$169k worth of stock

Executive VP exercised options and sold US$146k worth of stock

We Think Akero Therapeutics (NASDAQ:AKRO) Can Afford To Drive Business Growth

President exercised options and sold US$189k worth of stock

Executive VP exercised options and sold US$99k worth of stock

Executive VP exercised options and sold US$98k worth of stock

Price target decreased to US$53.00